Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra (Kineret®) in Patients With Still's Disease (SJIA and AOSD)

NCT03265132 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT03265132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03265132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra (Kineret®) in Patients With Still's Disease (SJIA and AOSD)
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 3
Overall status
Terminated
Start date
September 26, 2017
Completion date
May 23, 2019
Enrollment
13 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

still's disease, adult-onset, still's disease, juvenile-onset